About US
Contact us
-
Assessment of Abuse Potential of Drugs DRAFT GUIDANCE20100203(3).rar2010/2/3
-
HORIBA Medical launches Pentra C200 compact chemistry analyserHORIBA Medical has launched its new Pentra C200 compact chemistry analyser. Designed as an economical option for smaller sized laboratories, the Pentra C200 incorporates standards usually only found i2010/2/3
-
Aegis Therapeutics Announces Strategic Alliance With Dr. Reddy’s & Phase I Clinical StudyAegis Therapeutics, LLC and Dr. Reddy’s Laboratories recently announced a partnership providing Dr. Reddy’s access to Aegis’ Intravail drug delivery technology for certain undisclosed therapeu2010/2/3
-
Penwest Announces Initiation of Phase IIa Clinical Trial of A0001 in Patients With Friedreich's AtaxiaPenwest Pharmaceuticals Co. recently announced that it initiated a Phase IIa clinical trial for A0001 in December and that the screening of patients is underway. The study is being conducted a2010/2/2
-
Copley Scientific Launches World’s First Commercial Apparatus for Dissolution Testing of Inhaled DrugsCopley Scientific has launched the world’s first commercially available apparatus designed specifically for dissolution testing of inhaled drug formulations. Based on a concept developed by Pr2010/2/2
-
Altea & KAI Enter Development Agreement for the Transdermal Delivery of PeptidesAltea Therapeutics Corporation recently announced it has entered into a partnership with KAI Pharmaceuticals, Inc., a drug discovery and development company, for the preclinical and clinical d2010/2/2
-
NexMed Reports Technology Delivers Drugs Orally & With Enhanced BioavailabilityNexMed, Inc., a specialty CRO and a developer of products based on the NexACT technology, recently announced that preclinical results from its research and development group at Bio-Quant succe2010/2/1
-
Elan Drug Technologies Welcomes NDA Approval of MS Drug ER TabletsElan Drug Technologies, a business unit of Elan Corporation, plc, recently issued the following statement regarding the US FDA approval of AMPYRA (dalfampridine) as a treatment to improve walk2010/2/1
-
Invatec Launches Maris PlusInvatec has launched its latest self-expanding peripheral stent system, Maris Plus, in new 6, 7 and 8mm diameters. It is used for interventions involving the superficial femoral arteries (SFA). The 9,2010/2/1
-
BASF keeps R&D spending at high levelLong-term research strategy creates foundation for profitable growth International research Verbund with numerous cooperations secures competitive advantage CaRLa Catalysis Laboratory2010/1/29